10 Best Diabetes Stocks To Buy According to Billionaires

4. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Billionaires: 13

Dollar Value of Billionaire Holdings: $1,102,150,742

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), based in Boston, specializes in developing innovative treatments for serious diseases, with a focus on cystic fibrosis and type 1 diabetes (T1D) and stands fourth on our list of the 10 best diabetes stocks to buy according to billionaires. The company leverages cutting-edge technologies like CRISPR/Cas9 and stem cell therapies to address the root causes of diseases. It generates revenue through its cystic fibrosis drugs, Trikafta and Kalydeco, and is pioneering treatments for T1D, including VX-880, a stem cell-derived therapy aimed at restoring insulin production. Clinical trials have shown promising results, with patients achieving insulin independence, and the company is also developing VX-264, which eliminates the need for immunosuppressive therapies.

The corporation reported strong financial results for Q4 2024, with revenue of $2.91 billion, a 16% increase from the previous year. For the full year, 2024 revenue reached $11.02 billion, reflecting a 12% year-over-year growth. The company’s cystic fibrosis (CF) franchise, particularly the drug TRIKAFTA/KAFTRIO, contributed significantly to this growth, generating $10.24 billion in 2024. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) also ended the year with $11.2 billion in cash and investments, positioning itself for continued success.

In the diabetes treatment space, the company’s pipeline is showing promising progress. Its lead therapy, VX-880, a stem cell-derived treatment for type 1 diabetes (T1D), achieved positive Phase 1/2 trial results. Patients receiving the full dose of VX-880 showed successful islet cell engraftment and glucose-responsive insulin production. Additionally, three patients who followed up for at least 12 months met the primary endpoint of eliminating severe hypoglycemic events with HbA1c levels below 7%. The market for T1D is substantial, with VX-880 targeting 60,000 patients, including brittle diabetics and kidney transplant recipients. The corporation is also developing an encapsulated cell program to expand its reach to the broader T1D population.

Looking ahead, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is poised for continued growth, supported by recent FDA approvals, including ALYFTREK for CF patients and JOURNAVX for acute pain. These products, along with its robust pipeline, which includes four pivotal development programs, are expected to contribute to a projected 2025 revenue range of $11.75 to $12 billion. The company is also preparing for potential near-term launches of new treatments in CF and acute pain management.